🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Impact of Geriatric Assessment on the Treatment Plan of Elderly Patients With T2DM

RecruitingNAAges 60 Years - anyAllHospital de Clinicas de Porto Alegre
NCT06469437 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Introduction: With the aging of the world population and the increasing incidence of type 2 diabetes mellitus (T2DM) with age, the number of elderly individuals living with diabetes has been considerably rising. It is known that uncontrolled T2DM negatively impacts various health outcomes, including geriatric outcomes such as sarcopenia, frailty, immobility, incontinence, and infections. Current medical literature fails to establish appropriate glycemic targets for different elderly profiles. Although guidelines emphasize the need to individualize targets, there is no concise tool to identify which individuals benefit from each therapeutic approach. Data suggest that frailty is the best predictor of negative outcomes in elderly patients living with T2DM. The Clinical Frailty Scale (CFS) and the 10-minute Targeted Geriatric Assessment (TaGA-10) are validated tools for prognosis in elderly

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 60 years or older * Diagnostic of type 2 diabetes mellitus according to American Diabetes Association criteria * Patients under follow-up in a specialized endocrinology outpatient clinic * Patients who have a glycated hemoglobin measurement of up to three months Exclusion Criteria: * Lack of consent for research participation from the patient or the physician * Patients classified as Clinical Frailty Scale 9.
💊

What it tests

  • Providing the physicians with a proposed glycated hemoglobin target
📍

Where

1 site
Hospital de Clínicas de Porto Alegre
Porto Alegre, Brazil
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy